• About us
• Contact

Advertisement

Organisation › Details

Tubulis (Group)

Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its growing pipeline and will continue to collaborate with industry partners to usher in a new ADC era and deliver better outcomes for patients. *

 

	Start	2019-07-09 established (s-off)
	Industry	antibody-drug conjugate (ADC)
	Industry 2	antibody-drug conjugates (ADC) technology
	Person	Schumacher, Dominik (Tubulis 201907– Managing Director (CEO) + Co-Founder)
	Person 2	Helma-Smets, Jonas (Tubulis 201907– Managing Director (CSO) + Co-Founder)
	Region	Martinsried
	Country	Germany
	Street	19a Am Klopferspitz
	City	82152 Martinsried
		Address record changed: 2024-03-26
Basic data	Employees	n. a.
		* Document for »About Section«: Tubulis GmbH. (4/20/23). "Press Release: Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients". Munich.
		Record changed: 2024-03-26

Advertisement

More documents for Tubulis (Group)

• [1] Tubulis GmbH. (3/14/24). "Press Release: Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline". Munich....
• [2] Tubulis GmbH. (3/5/24). "Press Release: Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024". Munich....
• [3] Tubulis GmbH. (4/20/23). "Press Release: Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients". Munich....
• [4] Tubulis GmbH. (5/3/22). "Press Release: Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies". Munich....
• [5] Tubulis GmbH. (7/21/20). "Press Release: Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates". Munich....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.